Abstract
In order to describe the clinical and serologic features of a cutaneous vasculitis due to cocaine contaminated with the adulterant levamisole, we report four new cases of this syndrome along with 12 previously reported cases identified through a PubMed Literature search (1964 to March 2011). Of the 16 patients described, the average age was 43, with a female predominance (81% of patients). Over half of patients had involvement of the earlobes, and the rash frequently affected the extremities in a “retiform” pattern. Leukopenia or neutropenia was reported in 56% of patients. Ninety-three percent were anti-neutrophil cytoplasmic antibody positive, and 63% tested positive for anti-phospholipid antibodies. The predominant pattern seen on histopathological examination of the skin was small vessel vasculitis and/or a thrombotic vasculopathy. Treatment in these patients varied widely, with several patients showing improvement or resolution of the rash without specific therapy following cessation of illicit drug use. This new cutaneous vasculitis syndrome can be recognized by its characteristic rash and skin pathology, together with leukopenia and autoantibody production. Certain clinical features can be attributed to the adulterant levamisole, though cocaine as well may play a role in its pathogenesis.
Similar content being viewed by others
References
Bhinder S, Majithia V (2007) Cocaine use and its rheumatic manifestations. Clin Rheumatol 26:1192–1194
Bradford M, Rosenberg B, Moreno J, Dumyati G (2010) Bilateral necrosis of earlobes and cheeks: another complication of cocaine contaminated with levamisole. Ann Intern Med 152(11):758–759
Buchanan JA, Vogel JA, Eberhardt AM (2011) Levamisole-induced occlusive necrotizing vasculitis of the ears after use of cocaine contaminated with levamisole. J Med Toxicol 7(1):83–84
Walsh NMG, Green PJ, Burlingame RW, Pasternak S, Hanly JG (2010) Cocaine-related retiform purpura: evidence to incriminate the adulterant, levamisole. J Cutan Pathol 37(12):1212–1219
Waller JM, Feramisco JD, Alberta-Wszolek L, McCalmont TH, Fox LP (2010) Cocaine-associated retiform purpura and neutropenia: is levamisole the culprit? J Am Acad Dermatol 63(3):530–535
Farhat EK, Moorhead TT, Chaffing ML, Douglass MC (2010) Levamisole-induced cutaneous necrosis mimicking coagulopathy. Arch Dermatol 146(11):1320–1321
Click J (2011) Levamisole-induced retiform purpura. J Drug Dermatol 10(2):217
Geller L, Whang TB, Mercer SE, Phelps R (2011) Retiform purpura: a new stigmata of illicit drug use? Dermatol Online J 17(2):7
Han C, Sreenivasan G, Dutz JP (2011) Reversible retiform purpura: a sign of cocaine use. CMAJ. doi:10.1503/cmaj.101005
2003 National Survey on Drug Use and Health: Detailed Tables. US Department of Health and Human Services. Available at http://www.oas.samhsa.gov/Nhsda/2k3tabs/Sect1peTabs1to66.htm#tab1.38b. Accessed 26 April 2011
Amery WK, Bruynseels JP (1992) Levamisole, the story and the lessons. Int J Immunopharmacol 14(3):481–486
Runge LA, Pinals RS, Lourie SH, Tomar RH (1977) Treatment of rheumatoid arthritis with levamisole. A controlled trial. Arthritis Rheum 20(8):1445–1448
Christensen KD (1979) Treatment of seronegative spondylarthritis with levamisole: a double-blind placebo-controlled study. Int J Immunopharmacol 1(2):147–150
Tanphaichitr P, Tanphaichitr D, Sureeratanan J, Chatasingh S (1980) Treatment of nephrotic syndrome with levamisole. J Pediatr 96:490–493
Wauwe JV, Janssen PAJ (1991) On the biochemical mode of action of levamisole: an update. Int J Immunopharmacol 13(1):3–9
Chen LY, Lin YL, Chiang BL (2008) Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells. Clin Exp Immunol 151(1):174–181
Chang A, Osterloh J, Thomas J (2010) Levamisole: a dangerous new adulterant. Clin Pharmacol Ther 88(3):408–411
Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. US Department of Health and Human Services. Available at http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9Results.htm#2.1. Accessed 17 March 2011
Valentino AMM, Fuentecilla K (2005) Levamisole: an analytical profile. Microgram J 3(3-4):134–137
Centers for Disease Control and Prevention (CDC) (2009). Agranulocytosis associated with cocaine use—four states, March 2008–November 2009. MMWR 58(49):1381–1385
Menni S, Gianotti R, Ghio L, Edefonti A (1997) Ear lobe bilateral necrosis by levamisole-induced occlusive vasculitis in a pediatric patient. Pediatr Dermatol 14(6):477–479
Rongioletti F, Ghio L, Ginervi F et al (1999) Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children. Br J Dermatol 140:948–951
Powell J, Grech H, Holder J (2002) A boy with cutaneous necrosis occurring during treatment with levamisole. Clin Exp Dermatol 27(1):32–33
Scheinberg MA, Gomes Bezerra JB, Almeida FA, Silveira LA (1978) Cutaneous necrotizing vasculitis induced by levamisole. Br Med J 1(6110):408
Brewer JD, Meves A, Bostwick M, Hamacher KL, Pittelkow MR (2008) Cocaine abuse: dermatologic manifestations and therapeutic approaches. J Am Acad Dermatol 59(3):483–487
Friedman DR, Wolfsthal SD (2005) Cocaine-induced pseudovasculitis. Mayo Clin Proc 80(5):671–673
Willoughby MLN, Baird GM, Campbell AM (1977) Levamisole and neutropenia. Lancet 1(8012):657
Williams GT, Johnson SA, Dieppe PA, Huskisson EC (1978) Neutropenia during treatment of rheumatoid arthritis with levamisole. Ann Rheum Dis 37(4):366–369
Teerenhov L, Heinonen E, Gröhn P, Klefström P, Mehtonen M, Tiilikainen A (1978) High frequency of agranulocytosis in breast-cancer patients treated with levamisole. Lancet 2(8081):151–152
Rosenthal M, Breysse Y, Dixon AS et al (1977) Levamisole and agranulocytosis. Lancet 1(8017):904–905
Buchanan JA, Oyer RJ, Patel NR et al (2010) A confirmed case of agranulocytosis after use of cocaine contaminated with levamisole. J Med Toxicol 6:160–164
Wiens MO, Son WK, Ross C, Hayden M, Carelton B (2010) Cocaine adulterant linked to neutropenia. CMJA 182(1):57–59
Zhu MY, LeGatt DF, Turner AR (2009) Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Int Med 150(4):287–289
Knowles L, Buxton JA, Skuridina N et al (2009) Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia. Harm Reduction J 6:30
Hodinka I, Géher P, Merétey K, Gyódi EK, Petrányi GG, Bozsóky S (1981) Levamisole-induced neutropenia and agranulocytosis: association with HLA B27 leukocyte agglutinating and lymphocytotoxic antibodies. Int Arch Allergy Appl Immunol 65(4):460–464
Schmidt KL, Mueller-Eckhardt C (1977) Agranulocytosis, levamisole, and HLA-B27. Lancet 2(8028):85
Czuchlewski DR, Brackney M, Ewers C et al (2010) Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine. Am J Clin Pathol 133:466–472
Neynaber S, Mistry-Burchardi N, Rust C, Samtleben W, Burgdorf WH, Seitz MA, Messer G, Wollenberg A (2008) PR3-ANCA-positive necrotizing multi-organ vasculitis following cocaine abuse. Acta Derm Venereol 88(6):594–596
Fritsma GA, Leikin JB, Maturen AJ, Froelich CJ, Hryhorczuk DO (1991) Detection of anticardiolipin antibody in patients with cocaine abuse. J Emerg Med 9(Suppl 1):37–43
Wiesner O, Russel KA, Lee AS, Jenne DE, Trimarchi M, Gregorini G, Specks U (2004) Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 50(9):2954–2965
Kouassi E, Caille G, Lery L, Larivière L, Vézina M (1986) Novel assay and pharmacokinetics of levamisole and p-hydroxylevamsiole in human plasma and urine. Biopharm Drug Dispos 7(1):71–89
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gross, R.L., Brucker, J., Bahce-Altuntas, A. et al. A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clin Rheumatol 30, 1385–1392 (2011). https://doi.org/10.1007/s10067-011-1805-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1805-3